The state of Oklahoma deploys a high-risk legal strategy in a potentially precedent-setting case against opioid manufacturers.

The complaints add to a wave of litigation accusing Purdue of knowingly pushing doctors to prescribe OxyContin.

The verdict signals that the public is willing to hold pharmaceutical executives accountable for the U.S. crisis.

Federal prosecutors have brought the first criminal charges against pharmaceutical executives for illegally diverting opioids.

The first in a wave of lawsuits, the settlement could set the terms for other jurisdictions and companies looking to resolve the opioid litigation.

Anthem claims it's owed $20 billion in damages because of Cigna's intransigence in turning over information to push the merger forward.

Plaintiffs contend companies are illegally raising insulin prices to provide rebates for pharmacy-benefit managers who decide which drugs get on preferred insurance lists.

The trial of Insys Therapeutics Inc. CEO John Kapoor could serve as a test-drive for how jurors weigh claims of industry wrongdoing.